# Junta clínica — PT-pseudo_b9f0b7018502 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_b9f0b7018502",
  "pid": "PT-pseudo_b9f0b7018502",
  "task": 1,
  "psa": 8.7,
  "age": 54,
  "months": 1,
  "pirads": "5",
  "psad": 0.4,
  "psav": 1.21,
  "psap": 7.0,
  "vol": 23.0,
  "dre": "Normal",
  "bx": "Positive",
  "cspca": 0.8609265,
  "medhx": "Coronary artery disease",
  "meds": "atorvastatin, metoprolol",
  "notes": "PSA 8.7 ng/mL. PI-RADS 5. PSAD 0.40. Prostate volume 23 mL. csPCa 0.86.",
  "pmhx": [
    "Coronary artery disease"
  ],
  "allergies": [],
  "vitals": {
    "weight": "90 kg",
    "height": "182 cm",
    "bmi": "27.2",
    "bp": "97/85 mmHg",
    "hr": "82 bpm",
    "smoking": "Non-smoker",
    "last_dental": "6 mo ago",
    "flu_vax": "Nov 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "30 Jan 2025",
  "enc_ref": "Dr. L. Smits (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Ongoing monitoring of elevated prostate-specific antigen levels subsequent to a previously positive biopsy."
    },
    {
      "s": "History",
      "t": "An initial PSA elevation detected in mid-2022 prompted further investigation for this 54-year-old graphic designer. A subsequent targeted biopsy later established ISUP grade group 4 malignancy. He maintains a non-smoker status and shares his home with a partner, appreciating the adaptable nature of his self-employed design work. His coronary artery disease is managed with atorvastatin and metoprolol, and his most recent cardiology assessment noted stable angina with well-regulated lipid levels. He adheres to a daily 45-minute walking regimen while consuming alcohol in moderation. Lower urinary tract symptoms remain mild (IPSS 7/35), and a recent orthopaedic visit addressed a longstanding knee issue that continues to avoid surgical management. He has never married, listing his brother as his primary emergency contact."
    },
    {
      "s": "Physical examination",
      "t": "DRE reveals a prostate of uniform consistency and symmetry, devoid of nodular irregularities or focal asymmetry, consistent with a normal digital rectal examination. Vital signs remain stable throughout the general assessment, which shows no peripheral lymphadenopathy or abdominal masses."
    }
  ],
  "occupation": "graphic designer",
  "marital": "Never married",
  "living": "Lives with partner",
  "next_of_kin": "Sibling (brother)",
  "recent_other": [
    "Orthopaedic outpatient — knee follow-up"
  ],
  "alcohol": "5 units / week",
  "exercise": "Walking 45 min/day",
  "ipss": "IPSS score: 7/35 (mild LUTS)",
  "admin": "Patient self-employed; flexible appointment slots requested.",
  "mri_hospital": "Maastricht UMC+",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_b9f0b7018502
Task: 1

Encounter: Urology - outpatient on 30 Jan 2025.
Referrer: Dr. L. Smits (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 54-year-old male
  - PSA: 8.7 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.4 ng/mL²
  - PSA velocity: 1.21 ng/mL/yr
  - Prior PSA: 7.0 ng/mL
  - Prostate volume: 23.0 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8609265 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Coronary artery disease
  - Problem list / PMHx: Coronary artery disease
  - Current medication: atorvastatin, metoprolol
  - Allergies: NKA
  - Additional notes: PSA 8.7 ng/mL. PI-RADS 5. PSAD 0.40. Prostate volume 23 mL. csPCa 0.86.

Vitals: weight 90 kg, height 182 cm, BMI 27.2, BP 97/85 mmHg, HR 82 bpm. Smoking: Non-smoker.

Chief complaint: Ongoing monitoring of elevated prostate-specific antigen levels subsequent to a previously positive biopsy.

History: An initial PSA elevation detected in mid-2022 prompted further investigation for this 54-year-old graphic designer. A subsequent targeted biopsy later established ISUP grade group 4 malignancy. He maintains a non-smoker status and shares his home with a partner, appreciating the adaptable nature of his self-employed design work. His coronary artery disease is managed with atorvastatin and metoprolol, and his most recent cardiology assessment noted stable angina with well-regulated lipid levels. He adheres to a daily 45-minute walking regimen while consuming alcohol in moderation. Lower urinary tract symptoms remain mild (IPSS 7/35), and a recent orthopaedic visit addressed a longstanding knee issue that continues to avoid surgical management. He has never married, listing his brother as his primary emergency contact.

Physical examination: DRE reveals a prostate of uniform consistency and symmetry, devoid of nodular irregularities or focal asymmetry, consistent with a normal digital rectal examination. Vital signs remain stable throughout the general assessment, which shows no peripheral lymphadenopathy or abdominal masses.

Patient info: graphic designer; Never married; Lives with partner.
Next of kin: Sibling (brother).

Lifestyle: alcohol 5 units / week; exercise Walking 45 min/day; IPSS score: 7/35 (mild LUTS).

Recent other appointments: Orthopaedic outpatient — knee follow-up.
Admin: Patient self-employed; flexible appointment slots requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.63
  uncertainty  +/- 0.10 epistemic (95% band 0.43-0.84); among patients I cannot tell apart the outcome was 0.95 of 1.00 mixed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 60% of the time over the 20 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. The panel alone does not answer, and that is the finding.

The criterion here is that the visible panel does not determine this decision: he already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. What decides it is the documented grade of the prior biopsy and the surveillance history, which live in the previous notes. Measured on the labelled series: none of the three panel
rules I carry for this situation (PSA >= 20, age >= 78, PI-RADS <= 2) applies to him, and among the
39 remaining labelled men in this situation no structured variable separates the two answers.

REGISTRAR: the previous notes are where this case is decided. Read them for the grade of the prior
biopsy (Gleason or ISUP), the number of biopsy sessions and their dates, and whether he is on a
surveillance protocol with a confirmatory biopsy due. Do not read this as 'defer' and do not read it
as 'biopsy'.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 48 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 1.29: PI-RADS 5, PSA 12.0, PSAD 0.28, age 61, DRE Normal -> DEFER (borderline). He wrote: "Young patient with elevated PSA (>10), elevated PSA density, PIRADS5 and ISUP GG2 disease -> low threshold for recommending curative treatment. IF patient does not want…"
  2. distance 1.69: PI-RADS 5, PSA 4.53, PSAD 0.12, age 50, DRE Normal -> BIOPSY (clear). He wrote: "young patient with pirads5= high probability of significant prostate cancer and only one prev biopsy, increasing PSA. indicated with one more confirmatory biopsy to excl…"
  3. distance 1.81: PI-RADS 5, PSA 13.5, PSAD 0.452, age 66, DRE Normal -> BIOPSY (clear). He wrote: "PIRADS 5 lesion in a man in active surveillance."

PRECEDENT: BIOPSY (weighted vote 0.60 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 48 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes.
WHAT HE WEIGHS: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The EAU guidelines state that a repeat biopsy on MRI is mandated to confirm histological progression before a change in treatment strategy. A stable MRI (PRECISE 1-3) does not make a repeat biopsy superfluous but it might be excluded in patients with low-risk tumour and a stable PSA-D < 0.15.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
Expert 1's suggestion of biopsy is not decisive because the guideline makes the decision dependent on the MRI findings and the patient's risk profile, which are not fully established here. The precedent cited by Expert 1 is insufficient because it does not account for the specific context of this patient's prior positive biopsy status.

WHAT WE STILL NEED
The panel already contains: age (54), PSA (8.7 ng/mL), PI-RADS (5), PSA density (0.4), prostate volume (23.0 mL), DRE finding (Normal), prior-biopsy status (Positive), and csPCa probability (0.8609265).
The prior biopsy status is known, which is a factor the guideline makes decisive.
The documented grade of the prior biopsy and the number and dates of biopsy sessions in the notes are needed to determine the next step.
Whether the mpMRI prose compares against an earlier study is needed to assess the MRI stability.
The shape of the serial PSA is needed to assess the PSA trajectory.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges on establishing the grade and surveillance status from the previous notes, as the guideline requires this information to determine the next step.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> What is the lesion size and zone, extraprostatic extension, and whether it is compared against an earlier study?
  psa_trend (get_psa_trend) -> What is the shape of the serial PSA trajectory?
  previous_notes (get_previous_notes) -> What is the management context, including the prior biopsy grade, number/dates of sessions, and surveillance plan?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the documented grade (Gleason or ISUP) of the prior biopsy?
  Q2. What is the number and dates of prior biopsy sessions, and is the patient on a surveillance protocol with a confirmatory biopsy due?
  Q3. Does the mpMRI prose compare against an earlier study to assess MRI stability?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
The lesion size and zone is "spanning roughly 12 mm" at the "base-to-mid transition of the left posterior peripheral zone". Extraprostatic extension is "No extraprostatic extension or seminal vesicle involvement is observed". It is "compared against an earlier study" as the report is dated "28 January 2025" and the indication mentions "alongside a previously positive biopsy".
psa_trend
The shape of the serial PSA trajectory is increasing, with values: "Jun 2022, 3.1", "Feb 2023, 4.0", "Oct 2023, 5.2", "Jun 2024, 6.7", and "Jan 2025, 8.7".
previous_notes
The management context includes the prior biopsy grade being "Gleason 3+5 pathology", the number/dates of sessions being "not recorded", and the surveillance plan being "remains a key reference point in his current workup".

WHAT I DID NOT OPEN
I did not open the family-history anamnesis because the previous notes already mentioned the prior biopsy grade, which is the most critical piece of information requested by the moderator.

WHAT THIS SUPPORTS
Findings that argue FOR sampling this patient now:
PI-RADS 5 finding from the mpMRI report.
Increasing PSA trajectory from 6.7 ng/mL in Jun 2024 to 8.7 ng/mL in Jan 2025.

Findings that argue AGAINST sampling this patient now:
Prior positive biopsy status is known.
The previous notes state the prior biopsy grade was "Gleason 3+5 pathology".

WHERE THIS LEANS
The findings point towards a need for further clarification regarding the known prior diagnosis and surveillance status, which aligns with the EAU guideline's requirement for this information.
LEAN: biopsy

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 8.70 ng/mL over 5 points spanning 31 months; velocity +2.13 ng/mL per year; doubling time about 21 months.
PROJECTION at 6 months: 11.6 ng/mL, conformal 95% band 3.3-40.5.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report — the laboratory panel was not opened, so that block is imputed and my band is wider for it; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.62
  uncertainty  +/- 0.11 epistemic (95% band 0.42-0.83), of which 0.00 comes from values that had to be imputed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 56% of the time over the 25 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.63  ('supports' tier)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.62  ('supports' tier, fusion_nolab)
  EXPERT-LIBRARY     BIOPSY, p(biopsy)=0.60  (k=3 precedents)

  documented prior grade in the opened documents: GG 4 ("Gleason 3+5")

RULE THAT FIRED: documented prior grade GG 4 (Gleason 3+5) — carried by documented grade.
PANEL ANSWER: NO BIOPSY. A documented grade group of 2 or more is a treatment problem, not a sampling problem: the reading urologist deferred re-biopsy in 7 of the 8 labelled men with a recorded GG >= 2.
Dissenting on the board: EXPERT-STRUCTURED, EXPERT-FUSION, EXPERT-LIBRARY. Their bids are recorded above; they did not carry because a higher rung of the protocol applied.

Confidence the trace model expects here: clear. Weights it expects: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents opened—radiology_report, psa_trend, and previous_notes—have addressed all three moderator questions. The registrar reported the prior biopsy grade as "Gleason 3+5 pathology," which answers Q1. The notes stated the number/dates of sessions were "not recorded" and the plan was "remains a key reference point," addressing Q2. The radiology report confirmed it was "compared against an earlier study," addressing Q3.

ALIGNMENT WITH THE PANEL
The retrieved evidence, specifically the documented prior grade of "Gleason 3+5 pathology," aligns with the PANEL-PROTOCOL's decision to defer biopsy, as the protocol states that a documented grade group of 2 or more is a treatment problem, not a sampling problem.

THE OPEN QUESTIONS, ONE BY ONE
Q1. Answered by the Registrar: The documented grade is Gleason 3+5 pathology.
Q2. Answered by the Registrar: The number/dates of sessions were not recorded, and the surveillance plan remains a key reference point.
Q3. Answered by the Registrar: The report was compared against an earlier study.

WHAT CARRIES WEIGHT, AND WHY
The documented prior biopsy grade (Gleason 3+5) carries the most weight because the PANEL-PROTOCOL explicitly states this finding is the rule that fired, overriding the expert consensus. This finding dictates the management strategy according to the protocol.

MY SUGGESTION TO THE CHAIR
I suggest the decision should stand as per the PANEL-PROTOCOL's answer: defer biopsy, based on the documented Gleason 3+5 pathology.

VERDICT: ready | SUGGEST: defer | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: NO BIOPSY   (confidence: clear)

The decision to defer biopsy is based on the documented prior biopsy grade of Gleason 3+5 pathology, which the panel protocol identifies as a treatment problem rather than a sampling problem. This finding overrides the expert consensus suggesting biopsy, as the established high-grade disease dictates the management strategy. The evidence converged because the retrieved prior biopsy grade was the decisive factor, leading to a clear deferral recommendation.

What carried weight: bx=important, age=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Documents this conference opened: radiology_report, psa_trend, previous_notes
